Beaufond PLC announces 3rd Quarter 2019-20, Posts 62.16 % increase in EBITDA to USD 17.736 million of against USD 10.937 million to the corresponding period of last year.

Beaufond PLC continues to pursue its development strategy and once again delivers strong operating results, outperforming its industry. Beaufond PLC’s pharmaceutical business  has recorded an excellent performance in 2020, exhibiting once again the relevance of its strategy and its operational 阅读更多…

× How can I help you?